Proposals for Board of Directors and Redemption of Shares in Diamyd Medical
STOCKHOLM -- November 22, 2012
In connection with the work of the Nomination Committee the largest
shareholders of Diamyd Medical (STO:DIAMB)(Pink Sheets:DMYDY), Anders
Essen-Möller, Bertil Lindkvist and Östersjöstiftelsen, have also discussed the
future business and strategy of the Company. This has led to the following
Proposal to redeem shares for repayment to the shareholders It is planned to
offer the shareholders the opportunity to redeem every third share
(irrespective of class of shares) against a cash payment of SEK 12 per share.
This way MSEK 118.3 will be repaid to the shareholders. The proposal will be
put forward at an Extraordinary General Meeting planned to be held in the
second half of January 2013.
At that Extraordinary General Meeting it will also be proposed to resolve the
Statutory reserve, currently MSEK 96.6 according to the balance sheet to be
presented at the Annual General Meeting, into Non-restricted equity. This, in
combination with other measures to restructure the capital of the group,
creates preconditions for additional repayment to the shareholders in
connection with the 2013 Annual General Meeting.
Proposals for Board of Directors etc. The following proposals will be put
forward at the Annual General Meeting on December 6, 2012:
Election of Board of Directors and Remuneration Re-election of Anders
Essen-Möller and Maria-Teresa Essen-Möller and the election of new Board
members Erik Nerpin and Jonas Jendi. Lars Jonsson, Joseph Janes and Christer
Lindberg have declined re-election. Anders Essen-Möller is proposed to be
re-elected as Chairman of the Board.
Anders Essen-Möller is proposed to receive a total annual compensation of SEK
600,000 (SEK 1,140,000) as working Chairman of the Board. The other Board
members are proposed to receive an annual remuneration of SEK 125,000 each.
The total compensation to the Board thus amounts to SEK 975,000 and includes
remuneration for work on the audit committee, if one is appointed.
Erik Nerpin, born in 1961, is an attorney and partner at Kilpatrick Townsend
Jonas Jendi, born in 1970, M.Sc. Economics & Business Administration, has
spent the last 10 years managing the company Cogmed. Cogmed is based on
research from the Karolinska Institute and was acquired by Pearson in 2010.
Election of Auditor and Remuneration Re-election of Öhrlings
PricewaterhouseCoopers AB. Principal auditor is the authorized accountant Eva
Blom. It is proposed that the auditors should receive remuneration according
to approved account.
Chairman of the Meeting Attorney Erik Nerpin is proposed to be elected
Chairman of the Annual General Meeting.
Principles for the appointment of Nomination Committee for the 2013 Annual
General Meeting The Nomination Committee for the 2013 Annual General Meeting
is proposed to be appointed in essentially the same way that was approved at
the 2011 Annual General Meeting held on December 7, i.e. as follows. The
Nomination Committee shall be composed of representatives of the three largest
shareholders in the Company in terms of the number of votes and the Chairman
of the Board of Directors (issuing the call). The identity of the members of
the Nomination Committee must be made public not later than six months prior
to the 2013 Annual General Meeting. If the ownership structure changes
substantially before completion of the Nomination Committee's work, the
composition of the Nomination Committee may be changed. If a member leaves the
Nomination Committee before its work is complete, the other members shall
designate a replacement. The Nomination Committee will prepare proposals for
the following decisions at the 2013 Annual General Meeting: (i) election of
the Chairman of the Annual General Meeting, (ii) election of Board members and
the Chairman of the Board of Directors, (iii) Directors' remuneration, (iv)
election of the Company's auditors, (v) remuneration to the Company's
auditors, and (vi) rules for the nomination process for the 2014 Annual
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in Stockholm,
Sweden. The Company’s development project consists of the protein GAD65 for
the treatment and prevention of autoimmune diabetes. A Swedish
researcher-initiated Phase II study is ongoing to evaluate whether GAD65 can
prevent type 1 diabetes in children who are at high risk of developing the
Diamyd Medical also has holdings in the gene therapy company Periphagen,
Holdings Inc. (USA), the vaccine company Protein Sciences Corporation (USA)
and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the
Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is
available on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ) Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone:
+46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: firstname.lastname@example.org. Reg. no:
This information was brought to you by Cision http://www.cisionwire.com
President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26.
Press spacebar to pause and continue. Press esc to stop.